Regeneron Pharmaceuticals (NASDAQ:REGN) Trading 4.6% Higher on Analyst Upgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s stock price rose 4.6% during mid-day trading on Thursday after Wells Fargo & Company raised their price target on the stock from $615.00 to $700.00. Wells Fargo & Company currently has an equal weight rating on the stock. Regeneron Pharmaceuticals traded as high as $753.51 and last traded at $735.0420. Approximately 1,138,048 shares were traded during mid-day trading, an increase of 4% from the average daily volume of 1,097,857 shares. The stock had previously closed at $702.75.

Other equities analysts have also issued research reports about the company. Sanford C. Bernstein upped their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Finally, BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $776.81.

Insiders Place Their Bets

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Proficio Capital Partners LLC lifted its stake in Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 19 shares during the last quarter. Cove Private Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 4.5% during the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 20 shares in the last quarter. Marino Stram & Associates LLC increased its holdings in Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 20 shares during the last quarter. CoreCap Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 9.2% in the third quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 20 shares during the last quarter. Finally, Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

The stock has a fifty day simple moving average of $608.00 and a 200-day simple moving average of $573.41. The company has a market capitalization of $77.09 billion, a PE ratio of 17.57, a P/E/G ratio of 2.03 and a beta of 0.31. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $12.46 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.